Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Allergy
Published in: Clinical and Translational Allergy 1/2018

Open Access 01-12-2018 | Review

Atopic dermatitis in cats and dogs: a difficult disease for animals and owners

Authors: Natalie Katharina Yvonne Gedon, Ralf Steffen Mueller

Published in: Clinical and Translational Allergy | Issue 1/2018

Login to get access

Abstract

The purpose of this review article is to give an overview of atopic dermatitis in companion animals and of recent developments including knowledge on immunological background, novel treatment options and difficulties in disease management. The prevalence of hypersensitivities seems to be increasing. The pathogenetic mechanisms are not fully understood, yet multiple gene abnormalities and altered immunological processes are involved. In dogs and cats, the diagnosis of atopic dermatitis is based on history, clinical examination and exclusion of other differential diagnoses. Intradermal testing or testing for serum allergen-specific Immunoglobulin E is only used to identify allergens for inclusion in the extract for allergen immunotherapy. Symptomatic therapy includes glucocorticoids, ciclosporin, essential fatty acids and antihistamines. A selective janus kinase 1 inhibitor and a caninized monoclonal interleukin-31 antibody are the newest options for symptomatic treatment, although longterm effects still need to be assessed. The chronic and often severe nature of the disease, the costly diagnostic workup, frequent clinical flares and lifelong treatment are challenging for owners, pets and veterinarians. Patience and excellent communication skills are needed to achieve a good owner compliance and satisfactory clinical outcome for the animal.
Literature
1.
Mineshige T, Kamiie J, Sugahara G, Shirota K. A study on periostin involvement in the pathophysiology of canine atopic skin. J Vet Med Sci. 2018;80(1):103–11.PubMedCrossRef
2.
Marsella R, Girolomoni G. Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol. 2009;129(10):2351–7.PubMedCrossRef
3.
Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114(3–4):207–8.PubMedCrossRef
4.
Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol. 2001;81(3–4):147–51.PubMedCrossRef
5.
Marsella R, Olivry T, Carlotti DN. International Task Force on Canine Atopic D. Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol. 2011;22(3):239–48.PubMedCrossRef
6.
7.
Merryman-Simpson AE, Wood SH, Fretwell N, Jones PG, McLaren WM, McEwan NA, et al. Gene (mRNA) expression in canine atopic dermatitis: microarray analysis. Vet Dermatol. 2008;19(2):59–66.PubMedCrossRef
8.
Wood SH. The genetics of canine atopic dermatitis [Thesis]: Liverpool; 2010.
9.
Plager DA, Torres SM, Koch SN, Kita H. Gene transcription abnormalities in canine atopic dermatitis and related human eosinophilic allergic diseases. Vet Immunol Immunopathol. 2012;149(1–2):136–42.PubMedPubMedCentralCrossRef
10.
Schamber P, Schwab-Richards R, Bauersachs S, Mueller RS. Gene expression in the skin of dogs sensitized to the house dust mite Dermatophagoides farinae. G3 (Bethesda). 2014;4(10):1787–95.CrossRef
11.
Tengvall K, Kierczak M, Bergvall K, Olsson M, Frankowiack M, Farias FH, et al. Genome-wide analysis in German shepherd dogs reveals association of a locus on CFA 27 with atopic dermatitis. PLoS Genet. 2013;9(5):e1003475.PubMedPubMedCentralCrossRef
12.
Ardesjö-Lundgren B, Tengvall K, Bergvall K, Farias FHG, Wang L, Hedhammar A, et al. Comparison of cellular location and expression of Plakophilin-2 in epidermal cells from nonlesional atopic skin and healthy skin in German shepherd dogs. Vet Dermatol. 2017;28(4):377-e88.PubMedPubMedCentralCrossRef
13.
Shaw SC, Wood JL, Freeman J, Littlewood JD, Hannant D. Estimation of heritability of atopic dermatitis in Labrador and Golden Retrievers. Am J Vet Res. 2004;65(7):1014–20.PubMedCrossRef
14.
Nuttall T. The genomics revolution: will canine atopic dermatitis be predictable and preventable? Vet Dermatol. 2013;24(1):10-8 e3-4.PubMedCrossRef
15.
Verlinden A, Hesta M, Millet S, Janssens GP. Food allergy in dogs and cats: a review. Crit Rev Food Sci Nutr. 2006;46(3):259–73.PubMedCrossRef
16.
Picco F, Zini E, Nett C, Naegeli C, Bigler B, Rufenacht S, et al. A prospective study on canine atopic dermatitis and food-induced allergic dermatitis in Switzerland. Vet Dermatol. 2008;19(3):150–5.PubMedCrossRef
17.
Jaeger K, Linek M, Power HT, Bettenay SV, Zabel S, Rosychuk RA, et al. Breed and site predispositions of dogs with atopic dermatitis: a comparison of five locations in three continents. Vet Dermatol. 2010;21(1):118–22.PubMedCrossRef
18.
Olivry T, Dean GA, Tompkins MB, Dow JL, Moore PF. Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Exp Dermatol. 1999;8(3):204–11.PubMedCrossRef
19.
Schlotter YM, Rutten VP, Riemers FM, Knol EF, Willemse T. Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness. Vet Immunol Immunopathol. 2011;143(1–2):20–6.PubMedCrossRef
20.
Jassies-van der Lee A, Rutten VP, Bruijn J, Willemse AT, Broere F. CD4+ and CD8+ skin-associated T lymphocytes in canine atopic dermatitis produce interleukin-13, interleukin-22 and interferon-gamma and contain a CD25+ FoxP3+ subset. Vet Dermatol. 2014;25(5):456-e72.PubMedCrossRef
21.
Santoro D, Marsella R, Pucheu-Haston CM, Eisenschenk MN, Nuttall T, Bizikova P. Review: pathogenesis of canine atopic dermatitis: skin barrier and host-micro-organism interaction. Vet Dermatol. 2015;26(2):84-e25.PubMedCrossRef
22.
Marsella R, Papastavros V, Ahrens K, Santoro D. Decreased expression of caspase-14 in an experimental model of canine atopic dermatitis. Vet J. 2016;209:201–3.PubMedCrossRef
23.
List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY, et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol. 2003;163(4):901–10.PubMedPubMedCentralCrossRef
24.
Fanton N, Santoro D, Cornegliani L, Marsella R. Increased filaggrin-metabolizing enzyme activity in atopic skin: a pilot study using a canine model of atopic dermatitis. Vet Dermatol. 2017;28(5):479-e111.PubMedCrossRef
25.
Reiter LV, Torres SM, Wertz PW. Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls. Vet Dermatol. 2009;20(4):260–6.PubMedCrossRef
26.
Chermprapai S, Broere F, Gooris G, Schlotter YM, Rutten V, Bouwstra JA. Altered lipid properties of the stratum corneum in Canine Atopic Dermatitis. Biochim Biophys Acta. 2018;1860(2):526–33.CrossRef
27.
Yoon JS, Nishifuji K, Sasaki A, Ide K, Ishikawa J, Yoshihara T, et al. Alteration of stratum corneum ceramide profiles in spontaneous canine model of atopic dermatitis. Exp Dermatol. 2011;20(9):732–6.PubMedCrossRef
28.
Shimada K, Yoon JS, Yoshihara T, Iwasaki T, Nishifuji K. Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. Vet Dermatol. 2009;20(5–6):541–6.PubMedCrossRef
29.
Olivry T, Dunston SM. Expression patterns of superficial epidermal adhesion molecules in an experimental dog model of acute atopic dermatitis skin lesions. Vet Dermatol. 2015;26(1):53-6, e-17-8.PubMedCrossRef
30.
Reinero CR, DeClue AE, Rabinowitz P. Asthma in humans and cats: is there a common sensitivity to aeroallegens in shared environments? Environ Res. 2009;109(5):634–40.PubMedCrossRef
31.
Favrot C, Rostaher A, Fischer N. Clinical symptomps, diagnosis and therapy of feline allergic dermatitis. Schweiz Arch Tierheilkd. 2014;156(7):327–35.PubMedCrossRef
32.
Hobi S, Linek M, Marignac G, Olivry T, Beco L, Nett C, et al. Clinical characteristics and causes of pruritus in cats: a multicentre study on feline hypersensitivity-associated dermatoses. Vet Dermatol. 2011;22(5):406–13.PubMedCrossRef
33.
Ravens PA, Xu BJ, Vogelnest LJ. Feline atopic dermatitis: a retrospective study of 45 cases (2001–2012). Vet Dermatol. 2014;25(2):95-102, e27-8.PubMedCrossRef
34.
35.
Roosje PJ, Whitaker-Menezes D, Goldschmidt MH, Moore PF, Willemse T, Murphy GF. Feline atopic dermatitis. A model for Langerhans cell participation in disease pathogenesis. Am J Pathol. 1997;151(4):927–32.PubMedPubMedCentral
36.
Roosje PJ, Dean GA, Willemse T, Rutten VP, Thepen T. Interleukin 4-producing CD4+ T cells in the skin of cats with allergic dermatitis. Vet Pathol. 2002;39(2):228–33.PubMedCrossRef
37.
Diesel A. Cutaneous hypersensitivity dermatoses in the feline patient: a review of allergic skin disease in cats. Vet Sci. 2017;4(2):25.PubMedCentralCrossRef
38.
Rodrigues Hoffmann A, Patterson AP, Diesel A, Lawhon SD, Ly HJ, Elkins Stephenson C, et al. The skin microbiome in healthy and allergic dogs. PLoS ONE. 2014;9(1):e83197.PubMedPubMedCentralCrossRef
39.
Meason-Smith C, Diesel A, Patterson AP, Older CE, Johnson TJ, Mansell JM, et al. Characterization of the cutaneous mycobiota in healthy and allergic cats using next generation sequencing. Vet Dermatol. 2017;28(1):71-e17.PubMedCrossRef
40.
Szczepanik MP, Wilkolek PM, Adamek LR, Zajac M, Golynski M, Sitkowski W, et al. Evaluation of the correlation between Scoring Feline Allergic Dermatitis and Feline Extent and Severity Index and skin hydration in atopic cats. Vet Dermatol. 2018;29(1):34-e16.PubMedCrossRef
41.
Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol. 2001;81(3–4):255–69.PubMedCrossRef
42.
Favrot C. Clinical signs and diganosis of canine atopic dermatitis. Eur J Companion Anim Pract. 2009;19(3):219–22.
43.
Wilhem S, Kovalik M, Favrot C. Breed-associated phenotypes in canine atopic dermatitis. Vet Dermatol. 2011;22(2):143–9.PubMedCrossRef
44.
45.
Jensen-Jarolim E, Einhorn L, Herrmann I, Thalhammer JG, Panakova L. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy. 2015;5:15.PubMedPubMedCentralCrossRef
46.
Diesel A, DeBoer DJ. Serum allergen-specific immunoglobulin E in atopic and healthy cats: comparison of a rapid screening immunoassay and complete-panel analysis. Vet Dermatol. 2011;22(1):39–45.PubMedCrossRef
47.
Favrot C, Steffan J, Seewald W, Hobi S, Linek M, Marignac G, et al. Establishment of diagnostic criteria for feline nonflea-induced hypersensitivity dermatitis. Vet Dermatol. 2012;23(1):45-50, e11.PubMedCrossRef
48.
Bryan J, Frank LA. Food allergy in the cat: a diagnosis by elimination. J Feline Med Surg. 2010;12(11):861–6.PubMedCrossRef
49.
DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Vet Immunol Immunopathol. 2001;81(3–4):271–6.PubMedCrossRef
50.
Olivry T, Deboer DJ, Prelaud P, Bensignor E. International task force on canine atopic D. Food for thought: pondering the relationship between canine atopic dermatitis and cutaneous adverse food reactions. Vet Dermatol. 2007;18(6):390–1.PubMedCrossRef
51.
Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res. 2015;11:196.PubMedPubMedCentralCrossRef
52.
Kennis RA. Food allergies: update of pathogenesis, diagnoses, and management. Vet Clin North Am Small Anim Pract. 2006;36(1):175-84, vii-viii.PubMedCrossRef
53.
Bethlehem S, Bexley J, Mueller RS. Patch testing and allergen-specific serum IgE and IgG antibodies in the diagnosis of canine adverse food reactions. Vet Immunol Immunopathol. 2012;145(3–4):582–9.PubMedCrossRef
54.
Olivry T, Mueller RS, Prelaud P. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res. 2015;11:225.PubMedPubMedCentralCrossRef
55.
Martin A, Sierra MP, Gonzalez JL, Arevalo MA. Identification of allergens responsible for canine cutaneous adverse food reactions to lamb, beef and cow’s milk. Vet Dermatol. 2004;15(6):349–56.PubMedCrossRef
56.
Mueller RS, Olivry T, Prelaud P. Critically appraised topic on adverse food reactions of companion animals (2): common food allergen sources in dogs and cats. BMC Vet Res. 2016;12:9.PubMedPubMedCentralCrossRef
57.
Raditic DM, Remillard RL, Tater KC. ELISA testing for common food antigens in four dry dog foods used in dietary elimination trials. J Anim Physiol Anim Nutr (Berl). 2011;95(1):90–7.CrossRef
58.
Ricci R, Granato A, Vascellari M, Boscarato M, Palagiano C, Andrighetto I, et al. Identification of undeclared sources of animal origin in canine dry foods used in dietary elimination trials. J Anim Physiol Anim Nutr (Berl). 2013;97(Suppl 1):32–8.CrossRef
59.
Willis-Mahn C, Remillard R, Tater K. ELISA testing for soy antigens in dry dog foods used in dietary elimination trials. J Am Anim Hosp Assoc. 2014;50(6):383–9.PubMedCrossRef
60.
Horvath-Ungerboeck C, Widmann K, Handl S. Detection of DNA from undeclared animal species in commercial elimination diets for dogs using PCR. Vet Dermatol. 2017;28(4):373-e86.PubMedCrossRef
61.
Jackson HA, Jackson MW, Coblentz L, Hammerberg B. Evaluation of the clinical and allergen specific serum immunoglobulin E responses to oral challenge with cornstarch, corn, soy and a soy hydrolysate diet in dogs with spontaneous food allergy. Vet Dermatol. 2003;14(4):181–7.PubMedCrossRef
62.
Mueller RS, Olivry T. Critically appraised topic on adverse food reactions of companion animals (4): can we diagnose adverse food reactions in dogs and cats with in vivo or in vitro tests? BMC Vet Res. 2017;13(1):275.PubMedPubMedCentralCrossRef
63.
Jeffers J, Shanley K, Meyer E. Diagnostic testing of dogs for food hypersensitivity. J Am Vet Med Assoc. 1991;198:245–50.PubMed
64.
Fujimura M, Masuda K, Hayashiya M, Okayama T. Flow cytometric analysis of lymphocyte proliferative responses to food allergens in dogs with food allergy. J Vet Med Sci. 2011;73(10):1309–17.PubMedCrossRef
65.
Okayama T, Matsuno Y, Yasuda N, Tsukui T, Suzuta Y, Koyanagi M, et al. Establishment of a quantitative ELISA for the measurement of allergen-specific IgE in dogs using anti-IgE antibody cross-reactive to mouse and dog IgE. Vet Immunol Immunopathol. 2011;139(2–4):99–106.PubMedCrossRef
66.
Suto A, Suto Y, Onohara N, Tomizawa Y, Yamamoto-Sugawara Y, Okayama T, et al. Food allergens inducing a lymphocyte-mediated immunological reaction in canine atopic-like dermatitis. J Vet Med Sci. 2015;77(2):251–4.PubMedCrossRef
67.
Mueller RS, Fieseler KV, Rosychuk RA, Greenwalt T. Intradermal testing with the storage mite Tyrophagus putrescentiae in normal dogs and dogs with atopic dermatitis in Colorado. Vet Dermatol. 2005;16(1):27–31.PubMedCrossRef
68.
Lian TM, Halliwell RE. Allergen-specific IgE and IgGd antibodies in atopic and normal dogs. Vet Immunol Immunopathol. 1998;66(3–4):203–23.PubMedCrossRef
69.
Hillier A, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XVII): intradermal testing. Vet Immunol Immunopathol. 2001;81(3–4):289–304.PubMedCrossRef
70.
Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J. 2016;207:29–37.PubMedCrossRef
71.
Olivry T, Mueller RS. International task force on canine atopic D. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol. 2003;14(3):121–46.PubMedCrossRef
72.
Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol. 2009;20(2):84–98.PubMedCrossRef
73.
Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd. 2016;158(9):646–52.PubMedCrossRef
74.
Willemse A, Van den Brom WE, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184(10):1277–80.PubMed
75.
Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 2006;158(3):81–5.PubMedCrossRef
76.
Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(3):167–73.PubMed
77.
Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81(3–4):363–83.PubMedCrossRef
78.
Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res. 2001;62(3):307–10.PubMedCrossRef
79.
Mueller RS, Veir J, Fieseler KV, Dow SW. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis—a pilot study. Vet Dermatol. 2005;16(1):61–8.PubMedCrossRef
80.
Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9(6):537–43.PubMedCrossRef
81.
Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol. 2018;29(2):123-e49.PubMedCrossRef
82.
DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol. 2016;27(2):82-7e23.PubMedCrossRef
83.
Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol. 2016;27(6):478-e129.PubMed
84.
Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016;27(6):505-e136.PubMed
85.
Olivry T, Foster AP, Mueller RS, McEwan NA, Chesney C, Williams HC. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol. 2010;21(1):4–22.PubMedCrossRef
86.
Steffan J, Parks C, Seewald W. North American Veterinary Dermatology Cyclosporine Study G. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc. 2005;226(11):1855–63.PubMedCrossRef
87.
Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec. 2014;174(Suppl 2):3–12.PubMedPubMedCentralCrossRef
88.
Roberts ES, Speranza C, Friberg C, Griffin C, Steffan J, Roycroft L, et al. Confirmatory field study for the evaluation of ciclosporin at a target dose of 7.0 mg/kg (3.2 mg/lb) in the control of feline hypersensitivity dermatitis. J Feline Med Surg. 2016;18(11):889–97.PubMedCrossRef
89.
Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in veterinary dermatology. Vet J. 2012;193(2):317–25.PubMedCrossRef
90.
Last RD, Suzuki Y, Manning T, Lindsay D, Galipeau L, Whitbread TJ. A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. Vet Dermatol. 2004;15(3):194–8.PubMedCrossRef
91.
Lappin MR, Roycroft LM. Effect of ciclosporin and methylprednisolone acetate on cats previously infected with feline herpesvirus 1. J Feline Med Surg. 2015;17(4):353–8.PubMedCrossRef
92.
Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317–24.PubMedPubMedCentralCrossRef
93.
Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-97, e141-2.PubMedCrossRef
94.
Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-9, e35.PubMedCrossRef
95.
Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-30, e7-8.PubMedCrossRef
96.
Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Vet Dermatol. 2015;26(4):235-e52.PubMedCrossRef
97.
DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol. 2001;81(3–4):323–9.PubMedCrossRef
98.
Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210.PubMedPubMedCentralCrossRef
99.
Bizikova P, Papich MG, Olivry T. Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Vet Dermatol. 2008;19(6):348–57.PubMedCrossRef
100.
Eichenseer M. Klinische Wirkung der Antihistaminika Chlorpheniramin/Hydroxyzin (Histacalmine®) und Dimetinden (Fenistil®) bei atopischen Hunden. Munich: Ludwig-Maximilians-University; 2013.
101.
Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol. 2009;18(1):57–63.PubMedCrossRef
102.
Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004;309(1):404–13.PubMedCrossRef
103.
Baumer W, Stahl J, Sander K, Petersen LJ, Paps J, Stark H, et al. Lack of preventing effect of systemically and topically administered histamine H(1) or H(4) receptor antagonists in a dog model of acute atopic dermatitis. Exp Dermatol. 2011;20(7):577–81.PubMedCrossRef
104.
Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec. 2013;173(17):423.PubMedPubMedCentralCrossRef
105.
Dell DL, Griffin CE, Thompson LA, Griffies JD. Owner assessment of therapeutic interventions for canine atopic dermatitis: a long-term retrospective analysis. Vet Dermatol. 2012;23(3):228-e47.PubMedCrossRef
106.
Wildermuth K, Zabel S, Rosychuk RA. The efficacy of cetirizine hydrochloride on the pruritus of cats with atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover study. Vet Dermatol. 2013;24(6):576-81, e137-8.PubMedCrossRef
107.
Wagner I, Geh KJ, Hubert M, Winter G, Weber K, Classen J, et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec. 2017;181(5):118.PubMedCrossRef
108.
Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, et al. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol. 2009;20(3):191–8.PubMedCrossRef
109.
Nuttall TJ, McEwan NA, Bensignor E, Cornegliani L, Lowenstein C, Reme CA. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Vet Dermatol. 2012;23(1):4-10, e1-2.PubMedCrossRef
110.
Schmidt V, Buckley LM, McEwan NA, Reme CA, Nuttall TJ. Efficacy of a 0.0584% hydrocortisone aceponate spray in presumed feline allergic dermatitis: an open label pilot study. Vet Dermatol. 2012;23(1):11-6, e3-4.PubMedCrossRef
111.
Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol. 2004;15(5):294–303.PubMedCrossRef
112.
Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol. 2005;16(1):52–60.PubMedCrossRef
113.
Loflath A, von Voigts-Rhetz A, Jaeger K, Schmid M, Kuechenhoff H, Mueller RS. The efficacy of a commercial shampoo and whirlpooling in the treatment of canine pruritus—a double-blinded, randomized, placebo-controlled study. Vet Dermatol. 2007;18(6):427–31.PubMedCrossRef
114.
Schilling J, Mueller RS. Double-blinded, placebo-controlled study to evaluate an antipruritic shampoo for dogs with allergic pruritus. Vet Rec. 2012;171(4):97.PubMedCrossRef
115.
Harvey RG. Effect of varying proportions of evening primrose oil and fish oil on cats with crusting dermatosis (‘miliary dermatitis’). Vet Rec. 1993;133(9):208–11.PubMedCrossRef
116.
Bond R, Lloyd DH. A double-blind comparison of olive oil and a combination of evening primrose oil and fish oil in the management of canine atopy. Vet Rec. 1992;131(24):558–60.PubMed
117.
Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21(3):233–48.PubMedCrossRef
118.
Saevik BK, Bergvall K, Holm BR, Saijonmaa-Koulumies LE, Hedhammar A, Larsen S, et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol. 2004;15(3):137–45.PubMedCrossRef
119.
Muller MR, Linek M, Lowenstein C, Rothig A, Doucette K, Thorstensen K, et al. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis. Vet J. 2016;210:77–81.PubMedCrossRef
120.
Ohashi Y, Ushida K. Health-beneficial effects of probiotics: its mode of action. Anim Sci J. 2009;80(4):361–71.PubMedCrossRef
121.
Elmadfa I, Klein P, Meyer AL. Immune-stimulating effects of lactic acid bacteria in vivo and in vitro. Proc Nutr Soc. 2010;69(3):416–20.PubMedCrossRef
122.
Marsella R, Santoro D, Ahrens K, Thomas AL. Investigation of the effect of probiotic exposure on filaggrin expression in an experimental model of canine atopic dermatitis. Vet Dermatol. 2013;24(2):260-e57.PubMed
123.
de Roock S, van Elk M, van Dijk ME, Timmerman HM, Rijkers GT, Prakken BJ, et al. Lactic acid bacteria differ in their ability to induce functional regulatory T cells in humans. Clin Exp Allergy. 2010;40(1):103–10.PubMed
124.
Ohshima-Terada Y, Higuchi Y, Kumagai T, Hagihara A, Nagata M. Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis. Vet Dermatol. 2015;26(5):350-3, e74-5.PubMedCrossRef
125.
Marsella R. Evaluation of Lactobacillus rhamnosus strain GG for the prevention of atopic dermatitis in dogs. Am J Vet Res. 2009;70(6):735–40.PubMedCrossRef
126.
127.
Di Filippo P, Scaparrotta A, Rapino D, Cingolani A, Attanasi M, Petrosino MI, et al. Vitamin D supplementation modulates the immune system and improves atopic dermatitis in children. Int Arch Allergy Immunol. 2015;166(2):91–6.PubMedCrossRef
128.
Udompataikul M, Huajai S, Chalermchai T, Taweechotipatr M, Kamanamool N. The effects of oral vitamin d supplement on atopic dermatitis: a clinical trial with staphylococcus aureus colonization determination. J Med Assoc Thai. 2015;98(Suppl 9):S23–30.PubMed
129.
Klinger CJ, Hobi S, Johansen C, Koch HJ, Weber K, Mueller RS. Vitamin D shows in vivo efficacy in a placebo-controlled, double-blinded, randomised clinical trial on canine atopic dermatitis. Vet Rec. 2018;182(14):406.PubMedCrossRef
130.
131.
Gaschen FP, Merchant SR. Adverse food reactions in dogs and cats. Vet Clin North Am Small Anim Pract. 2011;41(2):361–79.PubMedCrossRef
132.
Jackson HA, Hammerberg B. The clinical and immunological reaction to a flavoured monthly oral heartworm prophylactic in 12 dogs with spontaneous food allergy. Vet Dermatol. 2002;13(4):218.
133.
Chesney CJ. Food sensitivity in the dog: a quantitative study. J Small Anim Pract. 2002;43(5):203–7.PubMedCrossRef
134.
Mueller R, Tsohalis J. Evaluation of serum allergen-specific IgE for the diagnosis of food adverse reactions in the dog. Vet Dermatol. 1998;9:167–71.CrossRefPubMed
135.
Valtolina C, Favier RP. Feline hepatic lipidosis. Vet Clin North Am Small Anim Pract. 2017;47(3):683–702.PubMedCrossRef
136.
DeBoer DJ, Marsella R. The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis. Vet Immunol Immunopathol. 2001;81(3–4):239–49.PubMedCrossRef
137.
Simou C, Thoday KL, Forsythe PJ, Hill PB. Adherence of Staphylococcus intermedius to corneocytes of healthy and atopic dogs: effect of pyoderma, pruritus score, treatment and gender. Vet Dermatol. 2005;16(6):385–91.PubMedCrossRef
138.
Wildermuth BE, Griffin CE, Rosenkrantz WS. Feline pyoderma therapy. Clin Tech Small Anim Pract. 2006;21(3):150–6.PubMedCrossRef
139.
Fazakerley J, Nuttall T, Sales D, Schmidt V, Carter SD, Hart CA, et al. Staphylococcal colonization of mucosal and lesional skin sites in atopic and healthy dogs. Vet Dermatol. 2009;20(3):179–84.PubMedCrossRef
140.
Yu HW, Vogelnest LJ. Feline superficial pyoderma: a retrospective study of 52 cases (2001–2011). Vet Dermatol. 2012;23(5):448-e86.PubMedCrossRef
141.
142.
Pali-Schöll I, De Lucia M, Jackson H, Janda J, Mueller RS, Jensen-Jarolim E. Comparing immediate-type food allergy in humans and companion animals-revealing unmet needs. Allergy. 2017;72(11):1643–56.PubMedCrossRef
143.
Meury S, Molitor V, Doherr MG, Roosje P, Leeb T, Hobi S, et al. Role of the environment in the development of canine atopic dermatitis in Labrador and golden retrievers. Vet Dermatol. 2011;22(4):327–34.PubMedCrossRef
144.
Pucheu-Haston CM, Bizikova P, Eisenschenk MN, Santoro D, Nuttall T, Marsella R. Review: the role of antibodies, autoantigens and food allergens in canine atopic dermatitis. Vet Dermatol. 2015;26(2):115-e30.PubMed
145.
Patterson AP, Schaeffer DJ, Campbell KL. Reproducibility of a commercial in vitro allergen-specific assay for immunoglobulin E in dogs. Vet Re. 2005;157(3):81–5.CrossRef
146.
Lee KW, Blankenship KD, McCurry ZM, Esch RE, DeBoer DJ, Marsella R. Performance characteristics of a monoclonal antibody cocktail-based ELISA for detection of allergen-specific IgE in dogs and comparison with a high affinity IgE receptor-based ELISA. Vet Dermatol. 2009;20(3):157–64.PubMedCrossRef
147.
Thom N, Favrot C, Failing K, Mueller RS, Neiger R, Linek M. Intra- and interlaboratory variability of allergen-specific IgE levels in atopic dogs in three different laboratories using the Fc-epsilon receptor testing. Vet Immunol Immunopathol. 2010;133(2–4):183–9.PubMedCrossRef
148.
Plant JD, Neradelik MB, Polissar NL, Fadok VA, Scott BA. Agreement between allergen-specific IgE assays and ensuing immunotherapy recommendations from four commercial laboratories in the USA. Vet Dermatol. 2014;25(1):15-e6.PubMedPubMedCentralCrossRef
149.
Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Dermatol. 2017;28(6):583-e141.PubMedCrossRef
150.
Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2. Vet Dermatol. 2017;28(2):183-e40.PubMed
151.
Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol. 2018;14:1.
152.
DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a review. Vet Dermatol. 2017;28(1):25-e6.PubMedCrossRef
153.
Sinke JD, Thepen T, Bihari IC, Rutten VP, Willemse T. Immunophenotyping of skin-infiltrating T-cell subsets in dogs with atopic dermatitis. Vet Immunol Immunopathol. 1997;57(1–2):13–23.PubMedCrossRef
154.
155.
Olivry T, Mayhew D, Paps JS, Linder KE, Peredo C, Rajpal D, et al. Early activation of Th2/Th22 inflammatory and pruritogenic pathways in acute canine atopic dermatitis skin lesions. J Invest Dermatol. 2016;136(10):1961–9.PubMedCrossRef
156.
Lee C-H. Immune regulation in pathophysiology and targeted therapy for itch in atopic dermatitis. Dermatol Sin. 2016;34:1–5.CrossRef
157.
Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118(4):930–7.PubMedCrossRef
158.
Mineshige T, Kamiie J, Sugahara G, Yasuno K, Aihara N, Kawarai S, et al. Expression of periostin in normal, atopic, and nonatopic chronically inflamed canine skin. Vet Pathol. 2015;52(6):1118–26.PubMedCrossRef
159.
Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74(23):4293–303.PubMedCrossRef
160.
Sung M, Lee KS, Ha EG, Lee SJ, Kim MA, Lee SW, et al. An association of periostin levels with the severity and chronicity of atopic dermatitis in children. Pediatr Allergy Immunol. 2017;28(6):543–50.PubMedCrossRef
161.
Olivry T, Hill PB. The ACVD task force on canine atopic dermatitis (XVIII): histopathology of skin lesions. Vet Immunol Immunopathol. 2001;81(3–4):305–9.PubMedCrossRef
162.
Correa da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol. 2015;135(3):712–20.PubMedCrossRef
163.
Piloto Valdes L, Gomez Echevarria AH, Valdes Sanchez AF, Ochoa Ochoa C, Chong Lopez A, Mier Naranjo G. Atopic dermatitis. Findings of skin biopsies. Allergol Immunopathol (Madr). 1990;18(6):321–4.
164.
Santoro D, Rodrigues Hoffmann A. Canine and human atopic dermatitis: two faces of the same host-microbe interaction. J Invest Dermatol. 2016;136(6):1087–9.PubMedCrossRef
165.
Meason-Smith C, Diesel A, Patterson AP, Older CE, Mansell JM, Suchodolski JS, et al. What is living on your dog’s skin? Characterization of the canine cutaneous mycobiota and fungal dysbiosis in canine allergic dermatitis. FEMS Microbiol Ecol. 2015;91(12):v139.CrossRef
166.
Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the skin microbiome in atopic dermatitis: a systematic review. Br J Dermatol. 2017;177(5):1272–8.PubMedCrossRef
167.
McCandless EE, Rugg CA, Fici GJ, Messamore JE, Aleo MM, Gonzales AJ. Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells. Vet Immunol Immunopathol. 2014;157(1–2):42–8.PubMedCrossRef
168.
Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol. 2018;29(1):69-e28.PubMedCrossRef
169.
Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007;204(8):1837–47.PubMedPubMedCentralCrossRef
170.
Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15(6):985–95.PubMedCrossRef
171.
Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J Invest Dermatol. 2011;131(1):150–7.PubMedCrossRef
172.
Asahina R, Nishida H, Kamishina H, Maeda S. Expression of IL-33 in chronic lesional skin of canine atopic dermatitis. Vet Dermatol. 2018;29:246-e91.PubMed
173.
Bruet V, Lieubeau B, Herve J, Roussel A, Imparato L, Desfontis JC, et al. Increased numbers of peripheral blood CD34+ cells in dogs with canine atopic dermatitis. Vet Dermatol. 2015;26(3):160-4, e33.PubMedCrossRef
174.
Hauck V, Hugli P, Meli ML, Rostaher A, Fischer N, Hofmann-Lehmann R, et al. Increased numbers of FoxP3-expressing CD4+ CD25+ regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity. Vet Dermatol. 2016;27(1):26-e9.PubMedCrossRef
Metadata
Title
Atopic dermatitis in cats and dogs: a difficult disease for animals and owners
Authors
Natalie Katharina Yvonne Gedon
Ralf Steffen Mueller
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Clinical and Translational Allergy / Issue 1/2018
Electronic ISSN: 2045-7022
DOI
https://doi.org/10.1186/s13601-018-0228-5

Other articles of this Issue 1/2018

Clinical and Translational Allergy 1/2018 Go to the issue

Study protocol

Early aggressive intervention for infantile atopic dermatitis to prevent development of food allergy: a multicenter, investigator-blinded, randomized, parallel group controlled trial (PACI Study)—protocol for a randomized controlled trial

Letter to the Editor

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

Research

Cross-sectional study on sensitization to mite and cockroach allergen components in allergy patients in the Central European region

Review

Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management

Review

An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity

Correction

Correction to: Better recognition, diagnosis and management of non-IgE-mediated cow’s milk allergy in infancy: iMAP—an international interpretation of the MAP (Milk Allergy in Primary Care) guideline